Skip to main content

Democratic Senator Cosponsors Three Marijuana Legalization Bills Amid Primary Challenge

Senate Majority Leader Mitch McConnell (R-KY) inserted language into a spending bill report on Thursday directing the Drug Enforcement Administration (DEA) to develop technology that can distinguish hemp from its “illicit cousin” marijuana.

The provision, which was attached to legislation to fund the Department of Justice for Fiscal Year 2020, is meant to support hemp manufacturers and regulators who must ensure that the crop is at or below a 0.3 percent THC content—the legal definition of hemp under the 2018 Farm Bill.

McConnell championed a measure in the wide-ranging agriculture legislation that federally legalized hemp and its derivatives, and he’s since devoted significant efforts to securing protections for the industry. For example, he backed provisions added to a separate appropriations bill last week that provides funding for the U.S. Department of Agriculture to implement hemp regulations.

“The Committee is aware that law enforcement and other agencies need to have access to laboratory testing and on-the-spot field testing technologies and devices to distinguish between hemp and marijuana,” McConnell’s report language states.

The panel notes current DEA research on the issue and is directing the agency to “report back to the Committee not later than 180 days after enactment of this act, and not less than every 6 months thereafter, until such time as technologies are identified and deployed to law enforcement in the field.”

“I stand ready to work with Kentucky’s hemp producers to address whatever challenges arise as they explore the full potential of this remarkable crop,” McConnell said of his latest provision. “Ensuring law enforcement can differentiate between industrial hemp and its illicit cousin is critical, and I’ll continue working with the DEA and other federal agencies so hemp can be treated the same as any other legal commodity.”

The measure, according to a McConnell press release, directs DEA to “to identify or develop on-the-spot field testing technologies” that would “enable law enforcement to distinguish between hemp and marijuana.”

DEA said in March that it was soliciting help to develop a device that can “provide specificity” in telling the cannabis cousins apart.

A separate provision in the new report “directs DEA to ensure the subsequent drug codes and scheduling guidance for marijuana (cannabis) and marijuana extracts shall be updated to reflect” the removal of hemp as a controlled substance.

In May, McConnell also added language to a disaster relief funding bill clarifying that hemp farmers are entitled to federal crop insurance.

Besides his hemp-specific advocacy, the senator has pushed the Food and Drug Administration (FDA) to develop rules allowing one of the crop’s derivatives, CBD, to be marketed as a food item or dietary supplement.

He asked the head of the FDA in a letter this month to clear a path for the lawful marketing of CBD products, urging the department to issue enforcement discretion guidelines so that CBD businesses know FDA will only target seriously bad actors as it develops long-term regulations.

Red the full language of the funding bill’s hemp provisions below:

Hemp Farming Act Guidance.—The Committee notes that the Agriculture Improvement Act of 2018 removed hemp and its derivatives from the Controlled Substances Act. The Committee appreciates DEA’s Notice on August 27, 2019, affirming the legal status of hemp, including hemp plants and cannabidiol [CBD] preparations at or below the 0.3 percent delta-9 tetrahydrocannabinol [THC] threshold, and directs DEA to ensure the subsequent drug codes and scheduling guidance for marijuana (cannabis) and marijuana extracts shall be updated to reflect this removal.

Hemp Testing Technology.—The Agriculture Improvement Act of 2018 removed hemp and its derivatives from the Controlled Substances Act, and authorized the production, consumption and sale of hemp and hemp-derived products in the United States. The Act requires random testing to ensure hemp meets the definition under the law of having a delta-9 THC concentration of less than 0.3 percent. The Committee is aware that law enforcement and other agencies need to have access to laboratory testing and on-the-spot field testing technologies and devices to distinguish between hemp and marijuana. The Committee is aware that DEA is conducting research in this area and has received responses to a Request for Information to identify any technology in the marketplace capable of providing field test kits. The Committee directs the DEA to continue to work to identify and/or develop such devices and technologies. The Committee further directs the DEA to report back to the Committee not later than 180 days after enactment of this act, and not less than every 6 months thereafter, until such time as technologies are identified and deployed to law enforcement in the field.

This story was updated to note the correct funding legislation that the hemp provision is attached to and to include the full language.

USDA Official Says There Are ‘Challenges’ Giving Hemp Farmers Insurance Coverage

Photo courtesy of Pixabay.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Original Article Source: https://www.marijuanamoment.net/democratic-senator-cosponsors-three-marijuana-legalization-bills-amid-primary-challenge/

Comments

Post a Comment

Popular posts from this blog

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...
Post a Comment
Read more

A Dozen US Governors Ask Congressional Leaders To Back Federal Marijuana Reform

A bipartisan coalition of 12 governors from states that have legalized medical or recreational cannabis  sent a letter to congressional leaders, asking for their support in getting a major marijuana reform bill through the U.S. House and Senate. The governors of California, Colorado, Maryland, Massachusetts, Nevada, New York, North Dakota, Oregon, Pennsylvania, Utah, Vermont and Washington state are backing  the STATES Act  – which would codify in federal law that marijuana regulations are to be left to the states instead of the federal government – while also seeking protections on banking and tax issues for the MJ industry. “The STATES Act is not about whether marijuana should be legal or illegal; it is about respecting the authority of states to act, lead and respond to the evolving needs and attitudes of their citizens,” the governors wrote. The letter also expressed support for the SAFE Banking Act , which was approved in March by a House committee. Tha...
Post a Comment
Read more

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...
Post a Comment
Read more